103 related articles for article (PubMed ID: 26271413)
1. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by doxorubicin-transferrin conjugate compared to free doxorubicin in the human leukemia cell lines.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Chem Biol Interact; 2014 Sep; 220():140-8. PubMed ID: 24998637
[TBL] [Abstract][Full Text] [Related]
3. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
Szwed M; Jozwiak Z
Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
[TBL] [Abstract][Full Text] [Related]
4. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Cell Oncol (Dordr); 2016 Apr; 39(2):107-18. PubMed ID: 26611752
[TBL] [Abstract][Full Text] [Related]
6. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
Szwed M; Kania KD; Jozwiak Z
Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T
Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872
[TBL] [Abstract][Full Text] [Related]
8. Molecular damage caused by generation of reactive oxygen species in the redox cycle of doxorubicin-transferrin conjugate in human leukemia cell lines.
Szwed M; Kania KD; Jozwiak Z
Leuk Lymphoma; 2015 May; 56(5):1475-83. PubMed ID: 25166006
[TBL] [Abstract][Full Text] [Related]
9. Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors.
Szwed M; Kania KD; Jozwiak Z
Int J Biochem Cell Biol; 2016 Jan; 70():57-67. PubMed ID: 26520467
[TBL] [Abstract][Full Text] [Related]
10. Changes in the activity of antioxidant barrier after treatment of K562 and CCRF-CEM cell lines with doxorubicin-transferrin conjugate.
Szwed M; Kania KD; Jozwiak Z
Biochimie; 2014 Dec; 107 Pt B():358-66. PubMed ID: 25312849
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.
Łubgan D; Jóźwiak Z; Grabenbauer GG; Distel LV
Cell Mol Biol Lett; 2009; 14(1):113-27. PubMed ID: 18850074
[TBL] [Abstract][Full Text] [Related]
12. Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines.
Suknuntha K; Thita T; Togarrati PP; Ratanachamnong P; Wongtrakoongate P; Srihirun S; Slukvin I; Hongeng S
Int J Hematol; 2017 Feb; 105(2):196-205. PubMed ID: 27766528
[TBL] [Abstract][Full Text] [Related]
13. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
14. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Pehlivan M; Caliskan C; Yuce Z; Sercan HO
Tumour Biol; 2017 May; 39(5):1010428317701654. PubMed ID: 28468589
[TBL] [Abstract][Full Text] [Related]
17. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-transferrin conjugate triggers pro-oxidative disorders in solid tumor cells.
Szwed M; Wrona D; Kania KD; Koceva-Chyla A; Marczak A
Toxicol In Vitro; 2016 Mar; 31():60-71. PubMed ID: 26607004
[TBL] [Abstract][Full Text] [Related]
19. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line.
Vangipuram SD; Buck SA; Lyman WD
Tumour Biol; 2012 Dec; 33(6):2173-83. PubMed ID: 22886526
[TBL] [Abstract][Full Text] [Related]
20. WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.
Chen S; Yuan X; Xu H; Yi M; Liu S; Wen F
Med Sci Monit; 2020 Jun; 26():e923799. PubMed ID: 32597418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
